Selexis CHO Cells in Suspension-1

Fact Sheets

Selexis enables biopharmaceutical companies to produce virtually any recombinant therapeutic protein, because we have the ability to understand and modify our cells to address productivity and expression challenges.

Map of nationalities present within Selexis employees + bar chart representing employees number increase over the years + pie chart of diploma level + pie chart of gender representation among employees and leadership

Selexis Diversity Snapshot

DECEMBER 14, 2022

At Selexis, diversity, inclusion, and equality have been a part of our DNA since our founding. Having varied perspectives drives innovation, impacts our products and services, and helps us better serve our partners and employees. While we have more work to do to advance diversity and inclusion, we are constantly growing, learning, and iterating to move our company forward.

VIEW PDF

Selexis Corporate Overview

OCTOBER 11, 2022

Selexis SA, a JSR Life Science Company, is the global leader in mammalian cell line development with best-in-class modular technology and highly specialized solutions that enable the life science industry to rapidly develop and commercialize innovative biotherapeutics and vaccines.

VIEW PDF

Selexis Capabilities

OCTOBER 11, 2022

For over 20 years, Selexis has helped its partners to predictably, rapidly and cost-effectively generate life-saving biologic medicines and vaccines. Its SUREtechnology PlatformTM is being used by global partners as one of the most robust CLD technologies worldwide.

VIEW PDF

JSR Life Sciences, KBI Biopharma, Selexis Overview

JULY 27, 2022

USING INNOVATION TO DE-RISK AND ACCELERATE THE DISCOVERY AND DEVELOPMENT OF NEW THERAPEUTICS

JSR Life Sciences brings together the best-in-class capabilities of its affiliates, deep biochemical knowledge and understanding of human disease biology, expertise in drug discovery and development, and access to capital into a single, integrated framework that creates value for its customers.

View PDF

Keywords: KBI Biopharma JSR Life Sciences Gene to GMP Selexis Contract Development Manufacturing Organization CDMO CMO cell line
SELEXIS Customer Survey Results Letter 2022

Selexis Customer Survey Results

JUNE 16, 2022

In 2022, Selexis surveyed our partners to collect feedback and gain insight about our company and technology. With our partners’ insights, we can build upon our business, continue to advance our technology and enhance our overall partner experience.

VIEW PDF

Selexis Rescue Promising Programs

JUNE 22, 2021

Solutions for complex human diseases are being addressed with increasingly complex protein therapeutic modalities. These include molecules such as bispecific proteins, DARPins, triabodies and novel scaffolds decorated with peptides, enzymes or growth factors, to name a few. Many, if not most, of these proteins do not exist in nature and producing them presents a range of production and secretion challenges such as ensuring appropriate folding and subunit pairing.

VIEW PDF